Break of consolidation IMU is trying to push through resistance.
Consolidating for a number of weeks.
Had a push today on above average volume.
Needs to get above 0.12 and have a daily close.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.0130 EUR
−93.15 M EUR
0.00 EUR
6.29 B
About IMUGENE LIMITED
Sector
Industry
CEO
Leslie Chong
Website
Headquarters
Sydney
Founded
1986
ISIN
AU000000IMU9
FIGI
BBG000QBRR16
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialization of immunotherapies against cancer. Its products include b-cell peptide cancer vaccines, arginine modulators, and mimotopes. The company was founded on May 30, 1986 and is headquartered in Sydney, Australia.
Imugene Limited (ASX: IMU) Director's Increase Stake"Imugene Limited (ASX: IMU) Director's Stake Update: On 12th Jan '24, a director affirmed their commitment by acquiring 1M RSUs at no cost, signaling bullish sentiment. Pre-acquisition, the director held 600K options and 20.73M shares, maintaining these post-acquisition. No options or shares were so
Finer Market Points: ASX Top 10 Momentum Stocks: 30 Nov 2023ASX:SHN ASX:TCG ASX:TG6 NYSE:STK SET:PLT ASX:VMM ASX:EQN ASX:FL1 ASX:IMU ASX:4DX
Momentum-leading shares are the market's best performers today. They are the fastest-growing shares on the ASX over the last 90 days. These companies can't get to be leaders without first appearing on
Box and Squeeze Strategy - Darvas InspiredDescription
The "Combined Box and Squeeze Strategy" is a comprehensive trading script developed for the TradingView platform. It merges two distinct analytical approaches: "The Box Percent Strat" and "Squeeze Box ," offering traders a multifaceted tool for market analysis.
Key Features
Box Perce
Trend Following and SMA CrossDescription:
This innovative trading strategy is a synergistic blend of two proven approaches: Trend Following and Simple Moving Average (SMA) Crossover. It harnesses the strengths of each to offer a more robust trading system designed for a variety of markets.
Key Features:
Trend Following Compo
Short as long as 0.459 is resistanceAlternative scenario: the upside breakout of 0.459 would call for 0.509 and 0.539.
My pivot point is at 0.459.
My preference: the downside prevails as long as 0.459 is resistance.
Comment:
The RSI is below its neutrality area at 50.
The MACD is negative and below its signal line.
The configu
IMU @ 18 NOV 2021Text me if you have any questions/comments for me.
-----
IMU
- Previous analysis was done on 4 Oct (red arrow) – suggested waiting for a successful rebound around 47.5 cents before plotting entry
- Since then, the stock has created a new high, retraced, and looks to be rebounding off the short-te
IMU @ 4 OCT 2021Text me if you have any questions/comments for me.
-----
IMU
- First time doing a written analysis on IMU
- Stock is currently trading at previous strong resistance (created in 2007)
- A good rebound from here would form a strong support at current levels
- A successful rebound looks to be at 0.47
$IMU measured move to determine exit priceA measured move calculation that is used to determine the exit price from a break out.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange IMUGENE LTD. stocks are traded under the ticker ILA.
We've gathered analysts' opinions on IMUGENE LTD. future price: according to them, ILA price has a max estimate of 0.26 EUR and a min estimate of 0.06 EUR. Watch ILA chart and read a more detailed IMUGENE LTD. stock forecast: see what analysts think of IMUGENE LTD. and suggest that you do with its stocks.
Yes, you can track IMUGENE LTD. financials in yearly and quarterly reports right on TradingView.
IMUGENE LTD. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
ILA earnings for the last half-year are −0.01 EUR per share, whereas the estimation was −0.01 EUR, resulting in a 0.00% surprise. The estimated earnings for the next half-year are −0.01 EUR per share. See more details about IMUGENE LTD. earnings.
IMUGENE LTD. revenue for the last half-year amounts to −964.63 K EUR, despite the estimated figure of 0.00 EUR. In the next half-year revenue is expected to reach 2.17 M EUR.
ILA net income for the last half-year is −50.39 M EUR, while the previous report showed −42.38 M EUR of net income which accounts for −18.89% change. Track more IMUGENE LTD. financial stats to get the full picture.
No, ILA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ILA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IMUGENE LTD. stock right from TradingView charts — choose your broker and connect to your account.